Biddle D A, Wells A, Dasgupta A
Department of Pathology and Laboratory Medicine, The University of Texas-Houston Medical School, 77030, USA.
Life Sci. 2000;66(2):143-51. doi: 10.1016/s0024-3205(99)00572-x.
Salicylate displaces phenytoin from protein binding leading to an increase in free phenytoin concentration. We observed unexpected decreases in free phenytoin concentration in the presence of salicylate. Serum pools containing no phenytoin or salicylate were supplemented with the same concentrations of phenytoin. Then to the aliquots of the individual pool, no salicylate (control), 150, 300 and 500 microg/ml of salicylate (therapeutic range: 15-300 microg/ml) were added. Specimens were incubated at 37 degrees C for 2 h and after re-equilibration at room temperature for 20 min, total and free phenytoin (in the protein free ultrafiltrates) concentrations were measured using fluorescence polarization immunoassay on the TDx/FLX analyzer. We observed an increase in free phenytoin concentration from 1.91 microg/ml (in the absence of salicylate) to 2.39 microg/ml in the presence of 500 microg/ml salicylate (total phenytoin: 13.3 microg/ml) in the normal pool. In sharp contrast, the free phenytoin concentrations decreased from an initial concentration of 3.82 microg/ml to 2.52 microg/ml in the presence of 500 microg/ml of salicylate (total phenytoin: 13.2 microg/ml) in the uremic pool. We also treated the uremic pool with activated charcoal. In the original uremic pool, the initial free phenytoin concentration was 3.05 microg/ml and the free concentrations then decreased to 2.28 microg/ml in the presence of 300 microg/ml of salicylate. In contrast, in the charcoal treated pool, the initial free phenytoin concentration increased from 1.61 microg/ml to 3.23 microg/ml in the presence of 300 microg/ml of salicylate. More interestingly when uremic toxins were extracted back from charcoal with methanol and the dry residue was added to an aliquot of normal serum, the normal serum behaved like a uremic serum and free phenytoin concentration was significantly decreased in the presence of salicylate. When an aliquot of methanol extract was studied by Matrix-Assisted Laser Desorption Ionization Mass Spectrometry (scan up to 10,000), we observed no peak at molecular weight over 551, indicating that these inhibitors are small molecules. We also identified hippuric acid as one of the inhibitors.
水杨酸盐会使苯妥英从蛋白结合位点上被置换出来,导致游离苯妥英浓度升高。但我们观察到,在水杨酸盐存在的情况下,游离苯妥英浓度却出现了意外下降。向不含苯妥英和水杨酸盐的血清样本中添加相同浓度的苯妥英。然后,向各个样本的等分试样中分别添加不含水杨酸盐(对照)、150、300和500微克/毫升的水杨酸盐(治疗范围:15 - 300微克/毫升)。将样本在37℃孵育2小时,在室温下再平衡20分钟后,使用TDx/FLX分析仪上的荧光偏振免疫分析法测量总苯妥英和游离苯妥英(在无蛋白超滤液中)的浓度。我们观察到,在正常样本中,当水杨酸盐浓度为500微克/毫升时(总苯妥英:13.3微克/毫升),游离苯妥英浓度从1.91微克/毫升(无水杨酸盐时)增加到了2.39微克/毫升。形成鲜明对比的是,在尿毒症样本中,当水杨酸盐浓度为500微克/毫升时(总苯妥英:13.2微克/毫升),游离苯妥英浓度从初始浓度3.82微克/毫升降至2.52微克/毫升。我们还用活性炭处理了尿毒症样本。在原始的尿毒症样本中,初始游离苯妥英浓度为3.05微克/毫升,在水杨酸盐浓度为300微克/毫升时,游离浓度降至2.28微克/毫升。相比之下,在经过活性炭处理的样本中,当水杨酸盐浓度为300微克/毫升时,游离苯妥英浓度从1.61微克/毫升增加到了3.23微克/毫升。更有趣的是,当用甲醇从活性炭中提取尿毒症毒素并将干燥残渣添加到一份正常血清中时,正常血清的表现就像尿毒症血清一样,在水杨酸盐存在的情况下,游离苯妥英浓度显著降低。当用基质辅助激光解吸电离质谱法(扫描范围高达10,000)研究一份甲醇提取物时,我们在分子量超过551处未观察到峰值,这表明这些抑制剂是小分子。我们还确定马尿酸是其中一种抑制剂。